Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides

AIDS

Volumn 24, Issue 17, 2010, Pages 2609-2618

  Kran, Anne Marte B ^a,b   Jonassen, Tom Øystein ^a   Sommerfelt, Maja A ^c   Løvgården, Gunilla ^a   Sørensen, Birger ^c   Kvale, Dag ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Bionor Immuno AS   (Norway)

Author keywords

amino acid substitutions; cellular immunity; gag protein p24; HIV 1; immune escape; peptides; therapeutic immunizations

Indexed keywords

AMINO ACID; EPITOPE; GAG PROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VACC 4X PEPTIDE;

AMINO ACID SUBSTITUTION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIREMIA;

EID: 78349309046     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833e502b     Document Type: Article

References (30)

1. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320:760-764.
2. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1:330-336.
3. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997; 3:205-211.
4. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, et al. Determinants of human immunodeficiency virus type 1 escape from the primaryCD8+ cytotoxic T lymphocyte response. J Exp Med2004; 200:1243-1256.
5. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan KM, et al. Selective escape from CD8+ T-cell responses re-presents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.J Virol2005; 79:13239-13249.
6. Althaus CL, De Boer RJ. Dynamics of immune escape during HIV/SIV infection. PLoS Comput Biol 2008; 4:e1000103.
7. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459.
8. Iversen AK, Stewart-Jones G, Learn GH, Christie N, Sylvester-Hviid C, Armitage AE, et al. Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nat Immunol 2006; 7:179-189.
9. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, Peyerl FW, et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-7375.
10. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-339.
11. Kran AM, Sørensen B, Nyhus J, Sommerfelt MA, Baksaas I, Bruun JN, et al. HLA-and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004; 18:1875-1883.
12. Kvale D, Kran AM, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, et al. Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia. AIDS 2005; 19:563-567.
13. Kran AM, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun JN, et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005; 23:4011-4015.
14. Kran AM, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006; 20:627-630.
15. Pettersen FO, Tasken K, Kvale D. Combined Env-and Gag-specific T cell responses in relation to PD-1 and CD4+ T cell loss rates in HIV-1 infection. Clin Exp Immunol2010; 161:315-323.
16. Asjö B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1357-1365.
17. Haslett PA, Nixon DF, Shen Z, Larsson M, Cox WI, Manandhar R, et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemo-therapy. J Infect Dis 2000; 181:1264-1272.
18. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
19. Korber BT, Osmanov S, Esparza J, Myers G. The World Health Organization Global Programme on AIDS proposal for stan-dardization of HIV sequence nomenclature. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retro-viruses 1994; 10:1355-1358.
20. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
21. Angulo R, Fulcher DA. Measurement ofCandida-specific blas-togenesis: comparison of carboxyfluorescein succinimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression. Cytometry 1998; 34:143-151.
22. Nyhus J, Kran AM, Sommerfelt MA, Baksaas I, Sørensen B, Kvale D. Multiple antigen concentrations in delayed-type hypersensi-tivity (DTH) and response diversity during and after immuniza-tion with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). Vaccine 2006; 24:1543-1550.
23. Lind A, Holmberg JO, Bengtsson P, Baksaas I, Sommerfelt MA, Sørensen B, Kvale D. Long-term proliferative CD4+ and CD8+ T cell memory 7 years after intradermal immunizations against short HIV Gag p24-like peptides targeting dendritic cells. Abstract #LBPE10, XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria.
24. Yang OO. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Trends Immunol 2004; 25:138-142.
25. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, et al. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 2008; 82:6434-6446.
26. Davenport MP, Loh L, Petravic J, Kent SJ. Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol2008; 16:561-566.
27. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 2009; 4:e6687.
28. Ciurea A, Hunziker L, Martinic MM, Oxenius A, Hengartner H, Zinkernagel RM. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat Med 2001; 7:795-800.
29. Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, et al. Human immunodeficiency virus type 1 escapes from inter-leukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations. J Virol 2009; 83:8722-8732.
30. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, Carlson JM, et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008; 205:1009-1017.